ATLANTA and SAN DIEGO, Nov. 13, 2022 (GLOBE NEWSWIRE) — Sofusa®, a wholly owned division of Sorrento Therapeutics SRNE “Sorrento”))) announced today that on Thursday 17th at 11:30am EST.

The event will provide an in-depth look and discussion of the clinical trial design and clinical data showing improved therapeutic outcomes and lymphatic function in patients with rheumatoid arthritis (RA) treated with the Sofusa Lymphatic Drug Delivery System (Sofusa). Patients enrolled in this study had an inadequate response to the standard dose of approved subcutaneous (sc) TNF inhibitor treatment, and 10 out of 10 patients achieved significant improvement in disease activity and lymphatic function after initiating lymphatic treatment with Sofusa at dose levels at half the previous SC dose or less. These data were accepted and presented today at the American College of Rheumatology (ACR) 2022 Convergence Meeting in Philadelphia.

Chris Jeffers, Ph.D., JD, Chief Executive Officer of Mayflower BioVentures and Hibiscus BioTechnology, will moderate this panel discussion following the ACR conference. The speakers at the event include:

• Roel Querubin, MD, board-certified rheumatologist, Atlanta Research Center for Rheumatology and Marrieta Rheumatology Associates
• Vibeke Strand, MD Adjunct Clinical Professor, Division of Immunology and Rheumatology, Stanford University School of Medicine
• Mike Royal, MD, Chief Medical Officer, Sorrento
• Brian Cooley, Senior Vice President, Head of Sofusa Lymphatic Drug Development
• Russell Ross, Ph.D., Chief Technical Officer, Sofusa Lymphatic Drug Development
  

To register for the live event, please visit the Online Experiences website. Detailed biographies of all speakers can be accessed here.

An archived replay following the live webcast…